Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 1312345...10...Last »

FDA approves Novartis’ leukemia treatment

The U.S. FDA approved Novartis AG’s Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders.

Read More »

Sanofi Delivers Robust Q1 2017 Financial Results

Sanofi’s net sales for first-quarter 2017 amounted to €8.65 billion, up 11.1% on a reported basis and 8.6% at CER, reflecting the acquisition of Boehringer Ingelheim’s CHC business and full consolidation of Sanofi’s European vaccine operations. At constant structure and CER, net sales for the 2017 first quarter were up 3.5% year over year.

Read More »

European Commission Extends Approval for Janssen’s Darzalex to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy

Janssen-Cilag International NV announced that the European Commission granted approval to Darzalex (daratumumab) for use in combination with lenalidomide and dexamethasone, or bortezomib – which is marketed as Velcade – and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Read More »

Biotech Unicorn Moderna’s Vaccine Performs Well in First Human Trial

There is excitement running through the halls of Moderna Therapeutics following the publishing of interim data from a Phase I study of its messenger RNA (mRNA) therapy for avian H10N8 influenza.

Read More »

FDA Approves BioMarin’s drug for Batten Disease

BioMarin Pharmaceutical announced that the U.S. FDA approved Brineura (cerliponase alfa) for the rare disease, late infantile neuronal ceroid lipofuscinosis type 2 (CLN2).

Read More »

Regeneron and Sanofi Announce Kevzara Biologics License Application Resubmission Accepted for Review by U.S. FDA

Regeneron Pharmaceuticals Inc. and Sanofi announced that the U.S. Food and Drug Administration accepted the resubmission of the Biologics License Application for Kevzara (sarilumab) as a Class I response with a two month review timeline. Per the Prescription Drug User Fee Act (PDUFA), the new target action date for the potential rheumatoid arthritis treatment is May 22, 2017.

Read More »

FDA approves Bayer’s Stivarga to treat most common liver cancer

The U.S. Food and Drug Administration said it approved Bayer AG’s drug Stivarga to treat liver cancer, the first such approval in nearly a decade.

Read More »

Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo

Bristol-Myers Squibb Co. reported higher-than-expected first-quarter 2017 earnings, helped by increased sales of the cancer drugs Opdivo and Yervoy and the blood thinner Eliquis.

Read More »

Celgene 1st quarter 2017 sales miss; expects psoriasis drug rebound

Celgene Corp. reported lower-than-expected first-quarter 2017 revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.

Read More »

AbbVie profit beats on Humira demand

AbbVie Inc. reported a larger-than-expected first-quarter 2017 profit, lifted by demand for the company’s flagship drug Humira.

Read More »

Mark Your Calendars: 4 Biotechs Facing FDA Decision Dates in May 2017

Here are four biotech companies with Prescription Drug User Fee Act (PDUFA) dates in May 2017 as the U.S. Food and Drug Administration reviews New Drug Applications.

Read More »

AstraZeneca Dumps Two Drugs From Pipeline

As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.

Read More »

Hello World

Hello world

Read More »

South Korea fines Novartis $49 million over kickbacks

South Korea fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company’s drugs.

Read More »

Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

Merck & Co.’s cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in 2016 sales.

Read More »

Messing with school operate? Term paper aid remedy to suit your needs!

Messing with school operate? Term paper aid remedy to suit your needs! Out of time? Burnt down your work deadlines? No tips for a typically reasonable report? We now have ready a whole lot for you!

Read More »

Messing with school operate? Term paper aid remedy to suit your needs!

Messing with school operate? Term paper aid remedy to suit your needs! Out of time? Burnt down your work deadlines? No tips for a typically reasonable report? We now have ready a whole lot for you!

Read More »

Anthem moving ahead on 2018 Obamacare insurance plans

Anthem Inc., which has 1.1 million customers in individual Obamacare plans, said it is moving ahead with its 2018 insurance filings but telling state regulators that it could increase premiums sharply and exit some markets.

Read More »

Finance chief quits drugmaker Teva

Teva Pharmaceutical Industries’ finance chief Eyal Desheh will step down, the second top official to resign from the Israel-based company during 2017.

Read More »

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors

Prevencio Inc. announced the publication of data which demonstrates that a simple, new blood test is more accurate than evaluating commonly used risk factors in determining whether a person will have a heart attack, stroke or major cardiac event. Researchers believe the data, published in the American Journal of Cardiology (AJC), could revolutionize how doctors identify patients – not only higher-risk patients who need aggressive treatment, but also lower-risk patients who could avoid expensive and invasive procedures.

Read More »

Page 1 of 1312345...10...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation